Xilong Scientific Co., Ltd. Logo

Xilong Scientific Co., Ltd.

002584.SZ

(1.5)
Stock Price

7,20 CNY

1.36% ROA

2.74% ROE

75.01x PER

Market Cap.

4.763.658.240,00 CNY

75.87% DER

0.25% Yield

0.75% NPM

Xilong Scientific Co., Ltd. Stock Analysis

Xilong Scientific Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Xilong Scientific Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (50%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

ROE in an average range (0.64%) suggests satisfactory profitability and decent utilization of shareholders' equity.

3 ROA

The stock's ROA (0.31%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

4 PBV

The stock's PBV ratio (2.68x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

5 Buffet Intrinsic Value

The company's stock seems undervalued (6.931) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Xilong Scientific Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Xilong Scientific Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Xilong Scientific Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Xilong Scientific Co., Ltd. Revenue
Year Revenue Growth
2008 766.705.162
2009 881.978.026 13.07%
2010 1.164.155.333 24.24%
2011 1.281.031.396 9.12%
2012 1.544.721.153 17.07%
2013 2.239.893.354 31.04%
2014 2.197.935.786 -1.91%
2015 2.513.529.316 12.56%
2016 2.928.383.508 14.17%
2017 3.394.989.818 13.74%
2018 3.355.078.356 -1.19%
2019 3.337.661.961 -0.52%
2020 6.243.170.933 46.54%
2021 6.837.667.633 8.69%
2022 6.183.208.812 -10.58%
2023 8.484.392.150 27.12%
2023 7.693.246.557 -10.28%
2024 9.042.072.820 14.92%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Xilong Scientific Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2008 4.451.120
2009 4.551.765 2.21%
2010 7.608.824 40.18%
2011 9.872.062 22.93%
2012 12.723.278 22.41%
2013 25.165.091 49.44%
2014 32.717.110 23.08%
2015 36.836.539 11.18%
2016 40.275.307 8.54%
2017 59.218.578 31.99%
2018 81.745.372 27.56%
2019 87.580.449 6.66%
2020 102.719.157 14.74%
2021 118.968.565 13.66%
2022 90.467.409 -31.5%
2023 93.836.562 3.59%
2023 95.701.006 1.95%
2024 89.418.652 -7.03%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Xilong Scientific Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 15.744.025
2009 11.788.346 -33.56%
2010 17.912.742 34.19%
2011 20.079.330 10.79%
2012 25.079.853 19.94%
2013 29.689.898 15.53%
2014 36.593.344 18.87%
2015 32.666.650 -12.02%
2016 34.578.251 5.53%
2017 39.473.687 12.4%
2018 38.347.467 -2.94%
2019 29.304.204 -30.86%
2020 41.319.779 29.08%
2021 49.761.967 16.97%
2022 29.449.679 -68.97%
2023 268.183.429 89.02%
2023 48.608.031 -451.73%
2024 -70.876.653 168.58%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Xilong Scientific Co., Ltd. EBITDA
Year EBITDA Growth
2008 67.955.676
2009 81.572.002 16.69%
2010 107.861.971 24.37%
2011 121.735.556 11.4%
2012 108.184.179 -12.53%
2013 99.029.867 -9.24%
2014 145.171.977 31.78%
2015 180.408.465 19.53%
2016 157.381.863 -14.63%
2017 148.484.412 -5.99%
2018 205.057.865 27.59%
2019 162.253.377 -26.38%
2020 176.712.349 8.18%
2021 368.860.107 52.09%
2022 234.967.767 -56.98%
2023 109.600.136 -114.39%
2023 178.195.920 38.49%
2024 272.068.040 34.5%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Xilong Scientific Co., Ltd. Gross Profit
Year Gross Profit Growth
2008 138.977.907
2009 160.758.878 13.55%
2010 212.627.085 24.39%
2011 235.949.096 9.88%
2012 248.808.810 5.17%
2013 266.701.113 6.71%
2014 374.402.375 28.77%
2015 419.076.084 10.66%
2016 437.881.396 4.29%
2017 460.741.757 4.96%
2018 537.469.826 14.28%
2019 532.075.982 -1.01%
2020 479.452.310 -10.98%
2021 557.419.105 13.99%
2022 441.500.962 -26.26%
2023 463.441.135 4.73%
2023 470.079.878 1.41%
2024 580.518.568 19.02%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Xilong Scientific Co., Ltd. Net Profit
Year Net Profit Growth
2008 46.703.430
2009 57.278.758 18.46%
2010 72.894.397 21.42%
2011 82.278.619 11.41%
2012 64.301.629 -27.96%
2013 48.607.493 -32.29%
2014 77.528.168 37.3%
2015 90.793.421 14.61%
2016 96.789.603 6.2%
2017 92.265.261 -4.9%
2018 70.577.607 -30.73%
2019 38.527.214 -83.19%
2020 58.187.577 33.79%
2021 187.064.486 68.89%
2022 89.063.745 -110.03%
2023 67.774.940 -31.41%
2023 33.347.824 -103.24%
2024 142.646.888 76.62%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Xilong Scientific Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Xilong Scientific Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2008 -19.379.151
2009 -8.368.618 -131.57%
2010 -8.558.342 2.22%
2011 -88.693.353 90.35%
2012 -79.225.579 -11.95%
2013 -86.010.146 7.89%
2014 7.238.097 1288.3%
2015 33.416.406 78.34%
2016 -71.493.366 146.74%
2017 -55.590.151 -28.61%
2018 -113.101.333 50.85%
2019 86.086.579 231.38%
2020 6.327.071 -1260.61%
2021 289.890.654 97.82%
2022 -514.590.406 156.33%
2023 46.248.630 1212.66%
2023 -499.962.210 109.25%
2024 -19.241.427 -2498.36%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Xilong Scientific Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2008 35.245.670
2009 49.543.766 28.86%
2010 40.155.818 -23.38%
2011 -34.244.486 217.26%
2012 13.554.377 352.65%
2013 32.283.126 58.01%
2014 104.508.649 69.11%
2015 128.791.427 18.85%
2016 11.002.035 -1070.61%
2017 -19.245.071 157.17%
2018 -97.102.373 80.18%
2019 95.892.729 201.26%
2020 44.571.222 -115.14%
2021 346.617.647 87.14%
2022 -190.882.684 281.59%
2023 46.035.052 514.65%
2023 -284.714.594 116.17%
2024 9.796.173 3006.39%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Xilong Scientific Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2008 54.624.821
2009 57.912.384 5.68%
2010 48.714.160 -18.88%
2011 54.448.867 10.53%
2012 92.779.956 41.31%
2013 118.293.272 21.57%
2014 97.270.551 -21.61%
2015 95.375.021 -1.99%
2016 82.495.401 -15.61%
2017 36.345.080 -126.98%
2018 15.998.960 -127.17%
2019 9.806.150 -63.15%
2020 38.244.150 74.36%
2021 56.726.993 32.58%
2022 323.707.722 82.48%
2023 -213.578 151664.17%
2023 215.247.616 100.1%
2024 29.037.600 -641.27%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Xilong Scientific Co., Ltd. Equity
Year Equity Growth
2008 265.414.494
2009 315.875.929 15.98%
2010 379.015.511 16.66%
2011 1.002.657.670 62.2%
2012 1.041.638.291 3.74%
2013 1.030.153.626 -1.11%
2014 1.137.983.648 9.48%
2015 1.797.625.790 36.7%
2016 1.810.502.336 0.71%
2017 1.724.836.748 -4.97%
2018 1.817.147.232 5.08%
2019 1.999.516.460 9.12%
2020 2.088.180.200 4.25%
2021 2.321.876.652 10.06%
2022 2.316.341.209 -0.24%
2023 2.348.123.358 1.35%
2023 2.354.056.092 0.25%
2024 2.308.139.897 -1.99%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Xilong Scientific Co., Ltd. Assets
Year Assets Growth
2008 464.968.892
2009 614.799.487 24.37%
2010 670.305.788 8.28%
2011 1.134.314.243 40.91%
2012 1.393.783.273 18.62%
2013 1.578.063.434 11.68%
2014 1.661.315.982 5.01%
2015 2.391.349.332 30.53%
2016 2.372.548.499 -0.79%
2017 2.482.978.929 4.45%
2018 3.509.208.885 29.24%
2019 4.230.935.377 17.06%
2020 4.421.453.856 4.31%
2021 4.724.032.726 6.41%
2022 4.977.416.163 5.09%
2023 4.904.170.681 -1.49%
2023 4.769.003.949 -2.83%
2024 4.850.180.255 1.67%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Xilong Scientific Co., Ltd. Liabilities
Year Liabilities Growth
2008 199.554.397
2009 298.923.557 33.24%
2010 291.290.276 -2.62%
2011 131.656.572 -121.25%
2012 352.144.981 62.61%
2013 547.909.807 35.73%
2014 523.332.333 -4.7%
2015 593.723.540 11.86%
2016 562.046.163 -5.64%
2017 760.561.750 26.1%
2018 1.692.061.653 55.05%
2019 2.231.418.916 24.17%
2020 2.333.273.655 4.37%
2021 2.402.156.073 2.87%
2022 2.661.074.952 9.73%
2023 2.556.047.323 -4.11%
2023 2.414.947.856 -5.84%
2024 2.521.378.768 4.22%

Xilong Scientific Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
14.46
Net Income per Share
0.11
Price to Earning Ratio
75.01x
Price To Sales Ratio
0.56x
POCF Ratio
173.63
PFCF Ratio
-251.13
Price to Book Ratio
2.07
EV to Sales
0.71
EV Over EBITDA
37.83
EV to Operating CashFlow
218.13
EV to FreeCashFlow
-315.49
Earnings Yield
0.01
FreeCashFlow Yield
-0
Market Cap
4,76 Bil.
Enterprise Value
5,98 Bil.
Graham Number
3.1
Graham NetNet
-0.5

Income Statement Metrics

Net Income per Share
0.11
Income Quality
0.43
ROE
0.03
Return On Assets
0.01
Return On Capital Employed
0.03
Net Income per EBT
0.86
EBT Per Ebit
0.84
Ebit per Revenue
0.01
Effective Tax Rate
0.15

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.06
Operating Profit Margin
0.01
Pretax Profit Margin
0.01
Net Profit Margin
0.01

Dividends

Dividend Yield
0
Dividend Yield %
0.25
Payout Ratio
0.92
Dividend Per Share
0.02

Operating Metrics

Operating Cashflow per Share
0.05
Free CashFlow per Share
-0.03
Capex to Operating CashFlow
1.69
Capex to Revenue
0.01
Capex to Depreciation
1.42
Return on Invested Capital
0.02
Return on Tangible Assets
0.01
Days Sales Outstanding
78.8
Days Payables Outstanding
28.6
Days of Inventory on Hand
30.02
Receivables Turnover
4.63
Payables Turnover
12.76
Inventory Turnover
12.16
Capex per Share
0.08

Balance Sheet

Cash per Share
0,91
Book Value per Share
3,98
Tangible Book Value per Share
3.7
Shareholders Equity per Share
3.93
Interest Debt per Share
3.08
Debt to Equity
0.76
Debt to Assets
0.36
Net Debt to EBITDA
7.72
Current Ratio
1.59
Tangible Asset Value
2,17 Bil.
Net Current Asset Value
0,91 Bil.
Invested Capital
2311637152
Working Capital
1,28 Bil.
Intangibles to Total Assets
0.03
Average Receivables
1,99 Bil.
Average Payables
0,77 Bil.
Average Inventory
611843639.5
Debt to Market Cap
0.37

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Xilong Scientific Co., Ltd. Dividends
Year Dividends Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2024 0 0%

Xilong Scientific Co., Ltd. Profile

About Xilong Scientific Co., Ltd.

Xilong Scientific Co., Ltd. researches and develops, manufactures, and sells chemical reagents in China. The company offers chemical reagents, PCB reagents, high purity reagents, food additives, active pharmaceutical and chemical materials, and lab glassware products. It also exports its products. The company was formerly known as Xilong Chemical Co., Ltd. and changed its name to Xilong Scientific Co., Ltd. in December 2015. Xilong Scientific Co., Ltd. was founded in 1983 and is based in Shantou, China.

CEO
Mr. Shao Qun Huang
Employee
1.159
Address
No. 2 Xilong Middle Street
Shantou, 510663

Xilong Scientific Co., Ltd. Executives & BODs

Xilong Scientific Co., Ltd. Executives & BODs
# Name Age
1 Mr. Zhenjie Huang
Vice President & Director
70
2 Mr. Ye Zhao
Vice President & Director
70
3 Mr. Shao Qun Huang
Chairman & Chief Executive Officer
70
4 Mr. Zhen Kai Huang
Vice Chairman of the Board of Directors & Vice President
70
5 Mr. Jia Niu
Chairman of the Supervisory Committee & Deputy GM of the Reagent Division
70

Xilong Scientific Co., Ltd. Competitors